Med-X, Inc. offering is now closed and is no longer accepting investments.

INVEST IN MED-X, INC. TODAY!

Cultivate and Innovate.

By innovating all-natural products, Med-X will provide safe and healthy cultivation practices and education to the emerging $5.4B cannabis industry. Embrace the future of Med-X by investing today! #InnovateTheEveryDay

This Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$6,999,210.60 Raised

REASONS TO INVEST

ABOUT

HEADQUARTERS
8236 Remmet Avenue
Canoga Park, CA 91304

By innovating all-natural products, Med-X will provide safe and healthy cultivation practices and education to the emerging $5.4B cannabis industry. Embrace the future of Med-X by investing today! #InnovateTheEveryDay

TEAM

Dr. David Toomey
Dr. David Toomey
CEO and Director

Dr. David Toomey’s professional life has been spent as a family physician for more than 24 years and a Hospice Medical Director for the last decade. Over his many years as a physician, Dr. Toomey has also worked as a clinical investigator developing and testing, in clinical trials for multiple companies including major pharmaceutical companies.

Matthew A. Mills
Matthew A. Mills
COO and President

COO and President of Med-X, Inc. since inception, Matthew Mills is the company’s visionary, he utilizes and implements his vast experience and knowledge in product development, operations, business development, manufacturing, marketing and crowdfunding to position the company for short-term and long-term growth.

Ronald J. Tchorzewski
Ronald J. Tchorzewski
CFO, Director

CFO and Director Med-X, Inc. since inception, Ron Tchorzewski has over thirty-five years of experience in financial accounting for start-up and development companies, as well as reporting for publicly held companies from Silicon Valley and beyond. His chief financial officer level support, including business plan development, capital structure, and day-to-day accounting experience positions Med-X, Inc. for financial success.

Jennifer Mills

Jennifer Mills

Vice President, Corporate Secretary, Director

Jennifer Mills has been the Executive Vice President, Director and corporate secretary of Med-X, Inc. since its inception, Jennifer Mills has worked for multiple companies in her career as a high-level accounting liaison as well as in Human Resources and project management.

Nick Phillips

Nick Phillips

Vice President, Editor-in-Chief

Began his career in the Hollywood entertainment world and moved into digital marketing for multiple products in Los Angeles, which led him to The Marijuana Times. He drives The Marijuana Times digital magazine to fill a void in the reporting of the cannabis industry by providing a voice, education and news about the cannabis community. His skill set coupled with his dedication and attention to detail gives The Marijuana Times the leading edge in the industry.

Dr. Allan Kurtz

Dr. Allan Kurtz

Director

Dr. Allan Kurtz is board-certified in internal medicine and has owned and operated Allan Kurtz, a Professional Medical Corporation, since 1986. Dr. Kurtz has been the Medical Director of Warner Medical Center and the California Center of Longevity Medicine. He is also a long-time member of the American Osteopathic College of Internal Medicine.

Dr. Morton Hyson

Dr. Morton Hyson

Director

Dr. Morton Hyson is in private practice as a Board-certified Neurologist in Las Vegas, Nevada. He is also a Clinical Assistant Professor at Touro University in San Francisco, California, where he has been educating since September 2000. His professional affiliations include the American Medical Association, the American Academy of Neurology, the American Academy of Neurological and Orthopedic Surgeons, the American Headache Society.

Frederick Dashiell, Jr.

Frederick Dashiell, Jr.

Director

Mr. Dashiell has held various teaching positions at educational institutions such as Chapman University in Orange, California, University of California at Los Angeles and California Institute of Technology. Mr. Dashiell has also held various positions as a computer scientist as well as a research scientist in the private sector. Mr. Dashiell received a Bachelor of Science degree in physics from the University of North Carolina at Chapel Hill in 1963 and a Ph.D. in mathematics from the University of California at Berkeley in 1973.

TERMS

Med-X, Inc.
Overview
PRICE PER SHARE
$0.60
DEADLINE
Jun 29, 2019
VALUATION
AMOUNT RAISED
$6,999,210.60
Breakdown
MIN INVESTMENT
$420
MAX INVESTMENT
$1,000,000
MIN NUMBER OF SHARES OFFERED
700
OFFERING TYPE
Equity
ASSET TYPE
SHARES OFFERED
MAX NUMBER OF SHARES OFFERED
25,000,000

Maximum Number of Shares Offered subject to adjustment for bonus shares

PRESS

Article Image
Nature-Cide, a Division of Pacific Shore Holdings, Inc. to Launch New Products and Labeling at National Hardware Show in Las Vegas, NV

Pacific Shore Holdings, Inc's. (OTCBB:PSHR), Nature-Cide Division, a pest management service company that's also engaged in the manufacturing of all-natural and eco-friendly pesticides, is excited to announce that they will be attending the National Hardware Convention in Las Vegas, NV, May 6 throug

Article Image
Med-X, Inc. and Nature-Cide Sign Leading Pest Control Company Pestmaster Services to Direct Distribution Deal

"We have been focused on using safe practices since 1979," said Van Diepen. "Nature-Cide is exactly the kind of product line our customers demand that we use. We have tested these products for months and the results are there. We have a shared culture and mission to reduce risk in our communities. T

Article Image
Nature-Cide Granular Insecticide

Nature-Cide Granular Insecticide is labeled for tick control, as well as for several other crawling pests and emerging larvae. The water-activated formula, which has 25(b)-exempt status, can be applied in the rain. It also can be added to fertilizer for a one-pass application on golf courses, turf,

Article Image
Going Green Again

Pennsylvanian Greg Pettis, a 23-year-veteran of the pest control industry, is an advocate of green pesticides. But that wasn’t always so.

Article Image
Med-X, Inc. will not be Affected Adversely by Attorney General Jeff Sessions Rescission of the Cole Memo

According to AP reports, Attorney General Jeff Sessions has rescinding the Cole Memo, which was the Obama administration's protection of state-compliant cannabis businesses that allowed for the legal cannabis industry to flourish across the country.

ALL UPDATES

01.18.20

New Shareholder Update on LIVE page

New Update Available on the New LIVE Reg. A+ Page. 

Click Here to See New Update

01.02.20

2019 Year-End Review and Outlook for 2020

Go to Live Investor Page -----> https://startengine.com/med-x

Happy New Year! As we close out the end of this amazing year I wanted to take some time and reflect back on a few important milestones the company was able to accomplish in 2019 and then cover some important items as we start 2020. It was a very productive year and we are set up nicely to have an even more productive year in 2020.

A year in review:

  • Nature-Cide products were introduced and sold to the professional turf grass industry for the first time.
  • Nature-Cide’s international footprint grew with Rentokil in several new countries.
  • Nature-Cide committed to a larger strategic marketing plan with the largest pest control distributors and industry publications.    
  • The company launched its Acquisition Company Roll-Up Strategy and entered into talks with several targets in the pest control service arena. 
  • The company signed a letter of intent and is working to close its first pest control service acquisition.  
  • The company reserved the Nasdaq Symbol “MXRX”.
  • Malibu Brands Pacific Pain Relief Cream was launched. 
  • The company successfully closed its first Regulation A+ offering on StartEngine in June of 2019 capping the round off in the neighborhood of $7 million raised since 2016.
  • The company signed with broker-dealer NMS Capital to partner on its new Regulation A+ capital raise. 
  • The company launched the National Investor Network. 
  • The Marijuana Times helped break the story on contaminated cannabis oil being sold on the black market. 
  • Thermal-Aid products saw growth from Cardinal Health Distribution and direct-to-consumers.
  • Nature-Cide delivered hundreds of samples of products to professionals in 2019 as the word spread around the world.  
  • The company launched its own investment platform for its new Regulation A+ offering.
  • The company surpassed its 2018 revenue in Q4 and reached its 2019 revenue goals. 

It was a challenging but satisfying year for our company. All of the support from our shareholders and partners allowed us to keep this movement going in a positive direction. The brands themselves, especially Nature-Cide, has become globally known as a premier Green Pest Control product line.

2020 is going to require everyone at the company to work harder than they have ever worked. This is the year where we pick up where we left off with direct-to-consumer sales for Thermal-Aid and explore a consumer revenue stream with Nature-Cide for the first time. Our media divisions are positioned to continue to grow especially the National Investor Network. The Equity Crowdfunding Report is already quickly positioning itself as the only media outlet using video to specifically cover the Equity Crowdfunding Markets and new private equity investors are learning about its resources. International pesticide label registration processes for many major countries are underway and we hope for this long process to be completed in 2020 opening the international flood gates for Nature-Cide. Conversations continue with our largest OTC healthcare distributor, Cardinal Health, to increase the footprint of the Thermal-Aid products as well as the introduction of the Malibu Brands Pacific Pain Relief Cream into OTC pharmacies. The company roll-up strategy is scheduled to go into overdrive as our first acquisition wraps up in legal and hopefully it will be announced in early 2020. We have several targets waiting in the wings to see how this first acquisition goes and we are hopeful other like-minded companies are going to want to be a part of this movement. NMS Capital is dedicated to continuing to support our efforts to bring in institutional partners into the mix as we continue our commitment to a listing on a national exchange when the time is appropriate. 

Without the continued support from each and every one of our shareholders we could not have made the progress we did this year. We all look forward to continuing the GREEN movement in these industries that are truly being forced to accept the changes coming. Natural products and services will have a place at the table in 2020 and many years beyond. 

The management team is committed to continuing to keep all of our shareholders apprised and updated on a regular basis, and in 2020 the team will continue to make ourselves available to all of our shareholders anytime. 

I wrapped up the year with an interview with our Chief Media Officer, Nick Philips, on the Equity Crowdfunding Report. It is a long, comprehensive interview. If you are interested in hearing more about 2019 and 2020, we cover many topics in the interview. We are all excited about the show and the buzz it is generating in the equity crowdfunding world. You can watch it by signing up, or logging in if you are already a member of the National Investor Network

Happy New Year!

Sincerely, 

Matthew Mills

President & COO


Video Interview

11.08.19

Med-X Surpasses 2018 Revenue During the 4th Quarter of 2019 While in Final Stages of it’s First Pest Control Service Acquisition

In this update, Matthew reports on how 2019 revenues have already surpassed 2018 revenues across multiple divisions as well as how its potential acquisition could lead to engagements with large scale investors. This progress has motivated Med-X Management to prepare the company accordingly, as they meet with the potential sponsors to list the company.

Please Visit New Campaign Page for New Important Full Company Update - NEW PAGE



DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

10.18.19

Nature-Cide Shines at PestWorld 2019

A new company update is now live on the New Campaign page. 


New Page - https://www.startengine.com/med-x


To see the update please visit the new page. 


Click Here to See New Update - https://www.startengine.com/med-x 

10.10.19

New Med-X Company Update - Nature-Cide Cannabis Cultivation Customers Should All Test Negative for the Harmful Chemicals Potentially Causing the Recent National Public Health Crisis

Please Visit New Campaign Page for New Important Company Update - https://www.startengine.com/med-x

09.30.19

New Company Update Live Now - Go to New Page

A new company update is now live on the New Campaign page. 


New Page - https://www.startengine.com/med-x


To see the update please visit the new page. 


Click Here to See New Update - https://www.startengine.com/med-x 

09.25.19

New Company Update Live Now - Go to New Page

A new company update is now live on the New Campaign page. 


New Page - https://www.startengine.com/med-x


To see the update please visit the new page. 


Click Here to See New Update - https://www.startengine.com/med-x 

08.21.19

Med-X, Inc. Qualified by the SEC to Launch Second Crowdfunding Offering in Conjunction with Investment Banking Firm NMS Capital Advisors, LLC

In this video update, COO, Matthew Mills, discusses the companies going forward strategy for raising capital with our investment banking partner, NMS Capital Advisors. He reveals a new version of the Malibu Brands Pacific Pain Relief Cream and also discusses the companies strategy to increase revenue via acquisitions to position the company to list on a national exchange like the Nasdaq. 

The press release can also be seen in its entirety below. 


To visit the New StartEngine Investment Page please visit the link here ---> New Page




Click Here for Video


Link to Press Release

LOS ANGELES, Aug. 15, 2019 /PRNewswire/ -- Med-X, Inc. -- On August 12, 2019, the Securities Exchange Commission (SEC) qualified Med-X, Inc. (Med-X) to begin the company's second Regulation A+ Equity Crowdfunding Offering. This time Med-X will be working with a Broker/Dealer, NMS Capital Advisors, LLC ("NMS Capital"), in selling the offering which is now live on the crowdfunding portal StartEngine.com. The company plans to also link and use its own web site resources which include, Med-X, Inc. the official company website, as well as placing links and information regarding the company's offering on its divisional and subsidiary web properties, such as Thermal-Aid, Nature-Cide, The National Investor Network, Malibu Brands and The Marijuana Times.

"Regulation A+ allows us to advertise and reach out to all investors, not just wealthy accredited investors who comprise the top few percent of the country. While we do have a large number of the wealthy accredited investors, it is our philosophy to let all of our customers who use our products and or services, our small business partners, friends, family and fans to all participate in our company mission," explained Med-X President and COO, Matthew Mills.

For this offering, while allowing the "Working Class American" to buy Med-X shares for as little as $420 for 525 shares, Med-X management and NMS Capital are working together to create a syndicated network of Broker/Dealers to accelerate the offering. This will provide Med-X with the ability to execute on immediate key growth strategies. 

For example, Med-X is in the midst of discussions and negotiations with multiple like-minded Eco-friendly pest control service companies, for strategic acquisition and or partnerships within the Nature-Cide's Service Division. This strategy is expected to fast-track the use of Nature-Cide's environmentally friendly and effective products within residential and wide-spread commercial applications nationwide. Other growth opportunities for Med-X divisions include adding new products to Nature-Cide's product line up, while expanding Malibu Brands new Pacific Pain Relief Cream to include a legal hemp CBD infused formulation version of the product, along with Thermal Aid's product lines and the Media Divisions, which includes the Marijuana Times and the new National Investor Network.

ABOUT MED-X, INC. 

Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced environmentally friendly green scene products and services sectors, with its Nature-Cide, Malibu Brands and Thermal-Aid divisions as well as the emerging hemp and cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compounds for the present medical industry demand. The company's digital magazine, The Marijuana Times, publishes high quality media content for the medical cannabis community to potentially generate revenue from advertisers as well as sell industry related merchandise to consumers. For more information regarding Med-X, Inc., please visit www.medx-rx.com, email info@medx-rx.com or call 818-349-2870.

DISCLAIMER AND FORWARD-LOOKING STATEMENTS 

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company. 

This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

06.28.19

Current Offering Closes Tonight

We wanted to remind everyone that today is the last day for our current Equity Crowdfunding Offering.

At midnight tonight, our current offering at $.60 for 700 shares with a minimum investment of $420 will expire. This is the last opportunity to participate in this offering.

We wanted to thank everyone for your support and participation over the past few months. We all share a common goal and together we will continue to make a difference. We are just getting started and we look forward to the next chapter ahead.

We could not be where we are today without all of you.

Matthew Mills

06.14.19

Current Offering Ending Soon

In this update, Matthew discusses the end of the Malibu Brands Pacific Pain Relief Cream Indiegogo campaign as well as the end of our current Regulation A+ offering coming in 11 days. 


WATCH VIDEO HERE

A special thank you goes out to all of our shareholders and supporters who backed the Indiegogo launch of the Malibu Brands new pain cream product. Today we shipped out orders to over 200 backers. You should have received an email with your tracking information. If you did not get an email with your tracking info let us know and we will send it over to you. Everything is going out Priority Mail so you should see it early next week. When you get it please let us know! 

In the coming weeks, we plan to follow up with the group of first backers so we can get your feedback on the product. Sharing your stories is going to be critical as we roll this out to retailers. We are currently in talks with a couple of retail product brokers as well as our current relationships with distributors and OTC pharmacy buyers.

If you were not able to participate in the launch and you would still like to get a jar you can order it directly from the website. 

https://malibu-brands.com

As you saw in the video, Matthew explains that as of today there are only 11 days left on our current Regulation A+ offering. On June 29th this offering will expire. If you have questions about this please make sure to call your company representative or contact us via email or phone. Below is a link to our latest filing with the Securities Exchange Commission. 

https://www.sec.gov/Archives/edgar/data/1620704/000147793219003131/medx_1a.htm

Thanks again to everyone who participated in the cream launch as well as the continued support from all of our shareholders.


info@medx-rx.com

818-349-2870 


Have a great weekend and Happy Fathers Day to all the Fathers in our shareholder group! 


No Offer or Solicitation Securities

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Med-X, Inc. Cautionary Statement Regarding Forward-Looking Statements

There may be statements in this communication that are, or could be, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and, therefore, subject to risks and uncertainties, including, but not limited to, statements regarding Med-X, Inc. or the combined company's future financial position, sales, costs, earnings, cash flows, other measures of results of operations, capital expenditures or debt levels are forward-looking statements. Words such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "should," "forecast," "project" or "plan" or terms of similar meaning are also generally intended to identify forward-looking statements. Med-X, Inc. cautions that these statements are subject to numerous important risks, uncertainties, assumptions and other factors, some of which are beyond Med-X, Inc.'s control, that could cause Med-X, Inc. or the combined company's actual results to differ materially from those expressed or implied by such forward-looking statements. To learn more about the Risk factors, please review Med-X, Inc.'s Regulation A+ Offering Circular.

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$6,999,210.60
INVESTORS
2,457
MIN INVEST
$420
VALUATION

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.